Diabetes News

For women with a history of gestational diabetes, moderate nut consumption – defined here as “weekly” – appeared to have a beneficial effect on kidney function.

The FDA granted breakthrough therapy designation to the SGLT2 inhibitor dapagliflozin for adults with chronic kidney disease with and without type 2 diabetes, according to an industry press release.

A study comparing patients with and those without type 2 diabetes found patients with diabetes had significantly higher rates of AKI than those without the condition.

Individuals engaged in time-restricted eating without any other intervention did not lose significantly more weight than individuals who ate throughout the day, a randomized clinical trial showed.

New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.

Treatment with dapagliflozin significantly reduced renal failure, cardiovascular death or hospitalization for heart failure, and prolonged survival among adults with chronic kidney disease with and without type 2 diabetes, study data show.

Using the Kidney Disease: Improving Global Outcomes criteria, researchers found patients with type 2 diabetes who were at higher risk for adverse cardiovascular and kidney outcomes reaped the most benefits from canagliflozin.

A high hemoglobin glycation index is associated with an increased risk for incident chronic kidney disease during 10 years of follow-up among treatment-naive adults with prediabetes or type 2 diabetes, according to a speaker.

Medicare Part D list prices in 2019 for the new, “novel” generation of second-line drugs for glycemic control sometimes cost hundreds of dollars more than the older “traditional” formulations of drugs, according to researchers.

Analyses of data from two clinical trials and a real-world study revealed an increased risk for anemia among adults with type 2 diabetes prescribed metformin.